China SXT Pharmaceuticals (SXTC) Competitors $0.38 0.00 (-0.03%) (As of 01:52 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestTrends SXTC vs. EYEN, VCNX, AIMD, VRAX, VIRX, CDIO, HOTH, BMRA, AEZS, and HURAShould you be buying China SXT Pharmaceuticals stock or one of its competitors? The main competitors of China SXT Pharmaceuticals include Eyenovia (EYEN), Vaccinex (VCNX), Ainos (AIMD), Virax Biolabs Group (VRAX), Viracta Therapeutics (VIRX), Cardio Diagnostics (CDIO), Hoth Therapeutics (HOTH), Biomerica (BMRA), Aeterna Zentaris (AEZS), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. China SXT Pharmaceuticals vs. Eyenovia Vaccinex Ainos Virax Biolabs Group Viracta Therapeutics Cardio Diagnostics Hoth Therapeutics Biomerica Aeterna Zentaris TuHURA Biosciences China SXT Pharmaceuticals (NASDAQ:SXTC) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Which has preferable earnings & valuation, SXTC or EYEN? China SXT Pharmaceuticals has higher revenue and earnings than Eyenovia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChina SXT Pharmaceuticals$1.93M0.81-$3.10MN/AN/AEyenoviaN/AN/A-$27.26M-$0.73-0.13 Does the media refer more to SXTC or EYEN? In the previous week, Eyenovia had 34 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 34 mentions for Eyenovia and 0 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.00 beat Eyenovia's score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment China SXT Pharmaceuticals Neutral Eyenovia Neutral Do institutionals & insiders hold more shares of SXTC or EYEN? 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.8% of Eyenovia shares are owned by institutional investors. 4.0% of China SXT Pharmaceuticals shares are owned by company insiders. Comparatively, 7.1% of Eyenovia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor SXTC or EYEN? Eyenovia received 92 more outperform votes than China SXT Pharmaceuticals when rated by MarketBeat users. Likewise, 64.68% of users gave Eyenovia an outperform vote while only 61.65% of users gave China SXT Pharmaceuticals an outperform vote. CompanyUnderperformOutperformChina SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% EyenoviaOutperform Votes17464.68% Underperform Votes9535.32% Is SXTC or EYEN more profitable? China SXT Pharmaceuticals has a net margin of 0.00% compared to Eyenovia's net margin of -114,639.41%. China SXT Pharmaceuticals' return on equity of 0.00% beat Eyenovia's return on equity.Company Net Margins Return on Equity Return on Assets China SXT PharmaceuticalsN/A N/A N/A Eyenovia -114,639.41%-1,108.24%-139.36% Do analysts prefer SXTC or EYEN? Eyenovia has a consensus target price of $2.00, suggesting a potential upside of 1,970.39%. Given Eyenovia's stronger consensus rating and higher probable upside, analysts plainly believe Eyenovia is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Eyenovia 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, SXTC or EYEN? China SXT Pharmaceuticals has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. SummaryEyenovia beats China SXT Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get China SXT Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTC vs. The Competition Export to ExcelMetricChina SXT PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.56M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A5.5095.1214.22Price / Sales0.81375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book0.0110.276.976.37Net Income-$3.10M$153.22M$118.73M$225.56M7 Day Performance-10.93%-1.19%-1.22%-0.02%1 Month Performance-43.60%-6.71%-3.07%2.04%1 Year Performance-77.85%32.39%32.52%28.00% China SXT Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTCChina SXT PharmaceuticalsN/A$0.380.0%N/A-80.0%$1.56M$1.93M0.0090EYENEyenovia3.0191 of 5 stars$0.10+4.5%$2.00+1,970.4%-93.2%$6.19MN/A0.0040Analyst DowngradeShort Interest ↓Analyst RevisionNews CoverageGap DownHigh Trading VolumeVCNXVaccinex0.5972 of 5 stars$3.57-3.8%N/A-70.2%$6.18M$570,000.00-0.0740AIMDAinos0.6838 of 5 stars$0.44+2.2%N/A-86.2%$6.08M$120,000.000.0046Gap DownVRAXVirax Biolabs Group0.2701 of 5 stars$1.88flatN/A-24.8%$6.07M$160,000.000.005VIRXViracta Therapeutics1.5718 of 5 stars$0.15-0.1%$5.00+3,196.0%-72.4%$6.03MN/A0.0020Analyst RevisionGap DownCDIOCardio Diagnostics2.1281 of 5 stars$0.25+1.1%$2.00+710.4%-89.0%$5.91M$20,000.000.007HOTHHoth Therapeutics2.3345 of 5 stars$0.85+3.0%$3.50+311.2%-22.0%$5.87MN/A-0.634News CoverageBMRABiomerica0.2078 of 5 stars$0.33+1.8%N/A-64.4%$5.55M$5.41M-0.8860News CoverageGap DownAEZSAeterna ZentarisN/A$2.98-0.7%N/A-57.4%$5.35M$2.37M-0.2020HURATuHURA Biosciences0.9613 of 5 stars$3.35+1.8%$15.00+347.8%N/A$5.33MN/A0.00N/ANegative NewsGap Up Related Companies and Tools Related Companies Eyenovia Alternatives Vaccinex Alternatives Ainos Alternatives Virax Biolabs Group Alternatives Viracta Therapeutics Alternatives Cardio Diagnostics Alternatives Hoth Therapeutics Alternatives Biomerica Alternatives Aeterna Zentaris Alternatives TuHURA Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SXTC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China SXT Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China SXT Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
